Phoenix NP Announces Availability of FDA-Approved Foundayo for Telehealth Patients in Arizona

PHOENIX, AZ - May 15, 2026 - PRESSADVANTAGE -

Phoenix NP has announced the availability of FDA-approved Foundayo (orforglipron) as part of its telehealth-based medical weight management services for eligible patients in Arizona. The introduction of this medication represents a recent addition to the treatment options offered through the organization’s remote care model.

Foundayo, the brand name for orforglipron, is a once-daily oral GLP-1 receptor agonist developed by Eli Lilly and approved by the U.S. Food and Drug Administration for chronic weight management in eligible adults. The medication is prescribed alongside a reduced-calorie diet and increased physical activity as part of a broader clinical approach to weight management.

Phoenix NP operates as a telehealth provider specializing in medical weight management services for women in Arizona. Through virtual consultations, patients can complete medical evaluations, receive treatment recommendations, and participate in follow-up care without attending in-person appointments. The addition of Foundayo expands the range of FDA-approved medications available within this care structure.

Foundayo is administered as an oral tablet taken once daily. According to available prescribing information, it may be taken at any time of day and does not require specific timing in relation to meals. Unlike injectable GLP-1 medications, it does not involve self-injection or refrigeration requirements, which may influence how some patients and providers approach treatment planning.

The availability of an oral GLP-1 receptor agonist reflects ongoing developments in weight management, with different formats being evaluated to address varying patient preferences and clinical considerations. Within Phoenix NP’s care model, medication selection is based on individual eligibility and medical assessment rather than a single standardized approach.

Jenny Vu, Founder and Provider of Phoenix NP, provided a statement regarding the update. “The addition of an oral GLP-1 option allows for broader consideration during treatment planning,” Jenny Vu said. “Each patient undergoes a clinical evaluation to determine whether a specific medication is appropriate based on their medical history and overall health profile.”

Foundayo’s approval was supported by clinical trials, including the ATTAIN Phase 3 program, which evaluated its use in adults with obesity or overweight. These studies examined the medication’s role when used alongside lifestyle modifications such as dietary changes and increased physical activity. The drug acts by activating GLP-1 receptors, which are involved in appetite regulation and gastric emptying.

Phoenix NP confirmed that all patients must complete a medical eligibility review before any prescription is issued. This process includes an assessment of medical history, current medications, and potential contraindications. Ongoing monitoring is also part of the care model, with follow-up consultations conducted through the organization’s telehealth platform.

The organization stated that it prescribes only medications approved by the U.S. Food and Drug Administration. Foundayo is included in this approach, and prescriptions are coordinated through authorized pharmacy channels. The provider does not rely on compounded alternatives.

Phoenix NP’s telehealth system is structured to provide continuity of care, with patients working with the same licensed provider throughout their treatment. This approach allows for consistent review of progress and adjustments to treatment plans when necessary. Communication is conducted through scheduled virtual visits and secure messaging systems.

The introduction of Foundayo into the provider’s offerings is being implemented across all service areas within Arizona, where Phoenix NP operates. The organization serves women residing in the state through its online platform, which supports appointment scheduling, consultations, and follow-up care.

This announcement reflects the addition of a newly approved medication within Phoenix NP’s existing services. The organization indicated that it will continue to evaluate FDA-approved treatment options as they become available, while maintaining its current clinical review standards for patient care.

###

For more information about Phoenix NP, contact the company here:

Phoenix NP
Michael Lim
(480) 382-0176
info@phoenixnptelehealth.com
1801 E Camelback Rd 102 1278, Phoenix, AZ 85016